Yale Bulletin and Calendar

October 13, 2006|Volume 35, Number 6


BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

DOWNLOAD FORMS

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Heart studies often don't include
kidney patients at high risk

Despite a high risk for cardiovascular death, patients with chronic kidney disease (CKD) are frequently excluded from cardiovascular trials, researchers at the School of Medicine report in the Journal of the American Medical Association.

The researchers also found that published trials provide no information on renal function in participants or the effect of interventions on participants with renal disease. This results in poor information on how to treat cardiovascular disease in CKD patients.

"Inclusion and reporting of kidney disease patients in cardiovascular trials must improve," says the senior investigator, Dr. Chirag Parikh, assistant professor in the Section of Nephrology at the School of Medicine. "Alternatively, we need to design separate trials for cardiovascular treatment exclusively in CKD patients."

Parikh and Steven Coca, renal fellow at Yale, reviewed 153 clinical trials for treatment of cardiovascular disease from 11 major medical and subspecialty journals published from 1985 through 2005. Patients with kidney disease were excluded from 56% of the trials and were also more likely to be excluded from multi-center trials. Only 5% of original articles reported the proportion of enrolled patients with renal disease and only 10% reported mean baseline renal function.

Cardiovascular death remains the leading cause of death in patients with CKD, and over nine million people in the United States have CKD.

Parikh and Coca, who are also affiliated with the Clinical Epidemiology Research Center at the VA Connecticut Healthcare System, say there are many biological reasons cardiovascular disease in patients with CKD may be different from that in general population and interfere with effectiveness of existing therapies and prognosis. Patients with CKD have abnormally high levels of protein in their urine, elevated homocysteine levels, and a higher burden of hypertension, anemia and inflammatory factors.

"We strongly urge researchers to universally adopt standards for reporting of renal disease in cardiovascular studies," says Parikh. "Funding agencies should make these studies a priority to gather information in this increasingly important subgroup of patients."

Other authors on the study included Dr. Harlan M. Krumholz and Dr. Amit X. Garg.

-- By Karen Peart


T H I SW E E K ' SS T O R I E S

Medical School receives $57.3 million NIH grant

Medical School receives $11.5 million to improve cancer diagnosis . . .

Museum technicians to show their own artworks at Open Studios

Student designs creative alternative to traditional construction fencing

MORE SCHOOL OF MEDICINE NEWS

Levin, Zedillo discuss the role of UNESCO at Paris event

'Women and Globalization' will be the topic of discussion . . .

Marketing executives and scholars to discuss latest trends

Australia's history and people are focus of film

Exhibit features paintings of England by Venetian artist 'Canaletto'

Lecture will examine the U.N. and 21st-century challenges

Lab talk

Play reading and talk will explore the romantic life of Benjamin Franklin

Tanner Lectures and related discussion to focus on humanities

'Crafting a Life' is the theme of this year's Law School reunions

Student research on early French songs culminates in . . .

Mutual interests

ALL gallery after-party celebrates artists in its newest exhibit and in CWOS

Campus Notes

Yale Books in Brief


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home